Cluster Headache Market Insight, Epidemiology and Market Forecast 2030

October 25 22:04 2021
Cluster Headache Market Insight, Epidemiology and Market Forecast 2030
DelveInsight Business Research LLP
DelveInsight’s ‘Cluster Headache Market’ report deliver an in-depth understanding of and historical and forecasted epidemiology as well as the market trends of Cluster Headache in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Cluster Headache Market

The Cluster Headache market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Cluster Headache symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Cluster Headache symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.

Cluster Headache Market Outlook

The Cluster Headache market outlook helps build a detailed comprehension of the historical, current, and forecasted Cluster Headache market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Cluster Headache market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Cluster Headache market in 7MM is expected to grow in the study period 2018–2030.

As per DelveInsight’s analysis, the number of patients suffering from the episodic form is much higher than those suffering from the chronic form. In the US, in 2018, there were 157,040 cases of the episodic form of CH and 39,260 cases of the chronic form of CH. These are projected to increase to 170,448 and 42,612 cases for episodic and chronic form, respectively. The treatment for cluster headache can be divided into three treatment phases: a fast-acting abortive treatment, preventive drugs, and transitional treatment to bridge the period between patients starting preventive drug dosages and the drugs asserting an effect. The acute treatment includes Triptans, High-flow oxygen, Somatostatin, and Somatostatin Analogues, among others. Prophylactic treatment drugs of the first choice are verapamil, lithium, and topiramate.

Key Findings

This section includes a glimpse of the Cluster Headache market in the 7MM.

The market size of Cluster Headache in the seven major markets was USD 741.8 million in 2020.

Cluster Headache Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Cluster Headache’s key players involved in developing targeted therapeutics.

Major players include Lundbeck Seattle BioPharmaceuticals and Winston Laboratories.

Request for sample pages @ Cluster Headache market 

Table of contents

1. Key Insights

2. Report Introduction

3. Cluster Headache Market Overview at a Glance

3.1. Market Share (%) Distribution of Cluster Headache in 2018

3.2. Market Share (%) Distribution of Cluster Headache in 2030

4. Executive Summary of Cluster Headache

5. Disease Background and Overview

5.1. Introduction

5.2. Classification of Cluster Headache

5.3. Clinical Characteristics

5.4. Comorbidities associated with Cluster Headache

5.5. Cluster Headache versus Migraine

5.6. Risk Factors associated with Cluster Headache

5.7. Pathophysiology

5.7.1. Trigeminovascular System

5.7.2. Parasympathetic Activation

5.7.3. Hypothalamus Activation

5.8. Diagnosis

5.8.1. Differential Diagnosis

5.9. Treatment

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Diagnosed Incident Population of Cluster Headache

6.3. Epidemiology of Cluster Headache

6.4. The United States

6.4.1. Prevalence of Cluster Headache in the United States

6.4.2. Diagnosed cases of Cluster Headache in the United States

6.4.3. Type-specific cases of Cluster Headache in the United States

6.4.4. Gender-specific cases of Cluster Headache in the United States

6.4.5. Age-specific cases of Cluster Headache in the United States

6.5. EU5

6.5.1. Germany

6.5.1.1. Prevalence of Cluster Headache in Germany

6.5.1.2. Diagnosed cases of Cluster Headache in Germany

6.5.1.3. Type-specific cases of Cluster Headache in Germany

6.5.1.4. Gender-specific cases of Cluster Headache in Germany

6.5.1.5. Age-specific cases of Cluster Headache in Germany

6.5.2. France

6.5.2.1. Prevalence of Cluster Headache in France

6.5.2.2. Diagnosed cases of Cluster Headache in France

6.5.2.3. Type-specific cases of Cluster Headache in France

6.5.2.4. Gender-specific cases of Cluster Headache in France

6.5.2.5. Age-specific cases of Cluster Headache in France

6.5.3. Italy

6.5.3.1. Prevalence of Cluster Headache in Italy

6.5.3.2. Diagnosed cases of Cluster Headache in Italy

6.5.3.3. Type-specific cases of Cluster Headache in Italy

6.5.3.4. Gender-specific cases of Cluster Headache in Italy

6.5.3.5. Age-specific cases of Cluster Headache in Italy

6.5.4. Spain

6.5.4.1. Prevalence of Cluster Headache in Spain

6.5.4.2. Diagnosed cases of Cluster Headache in Spain

6.5.4.3. Type-specific cases of Cluster Headache in Spain

6.5.4.4. Gender-specific cases of Cluster Headache in Spain

6.5.4.5. Age-specific cases of Cluster Headache in Spain

6.5.5. United Kingdom

6.5.5.1. Prevalence of Cluster Headache in the United Kingdom

6.5.5.2. Diagnosed cases of Cluster Headache in the United Kingdom

6.5.5.3. Type-specific cases of Cluster Headache in the United Kingdom

6.5.5.4. Gender-specific cases of Cluster Headache in the United Kingdom

6.5.5.5. Age-specific cases of Cluster Headache in the United Kingdom

6.6. Japan

6.6.1. Prevalence of Cluster Headache in Japan

6.6.2. Diagnosed cases of Cluster Headache in Japan

6.6.3. Type-specific cases of Cluster Headache in Japan

6.6.4. Gender-specific cases of Cluster Headache in Japan

6.6.5. Age-specific Cases of Cluster Headache in Japan

7. Organizations contributing towards Cluster Headache

8. Patient Journey

9. Case Reports

10 Marketed Products

10.1. EMGALITY (Galcanezumab-gnlm): Eli Lilly and Company

10.1.1. Product Description

10.1.2. Mechanism of action

10.1.3. Regulatory Milestones

10.1.4. Safety and Efficacy of EMGALITY

10.1.5. Product Profile

11. Emerging Therapies

11.1. Key Cross Competition

11.2. VYEPTI (Eptinezumab): Lundbeck Seattle BioPharmaceutical

11.2.1. Drug Description

11.2.2. Regulatory Milestones

11.2.3. Clinical Development

11.2.4. Clinical Trials Information

11.2.5. Safety and Efficacy

11.2.6. Product Profile

11.3. Civamide (Zucapsaicin): Winston Laboratories

11.3.1. Drug Description

11.3.2. Regulatory Milestones

11.3.3. Clinical Development

11.3.4. Clinical Trials Information

11.3.5. Safety and Efficacy

11.3.6. Product Profile

12. Other Drugs under Development

12.1. Zolmitriptan transdermal (C213): Zosano Pharma

12.1.1. Drug Description

12.1.2. Clinical Development

12.1.3. Clinical Trials Information

12.1.4. Product Profile

13. Cluster Headache: Seven Major Market Analysis

13.1. Key Findings

13.2. Market Size of Cluster Headache in 7MM

13.3. Market Outlook

13.4. United States Market Size

13.1.1. Total Market Size of Cluster Headache in the United States

13.1.2. Market Size of Cluster Headache by Therapies in the United States

13.5. EU-5 Market Size

13.5.1. Germany

13.5.1.1. Total Market Size of Cluster Headache in Germany

13.5.1.2. Market Size of Cluster Headache by Therapies in Germany

13.5.2. France

13.5.2.1. Total Market Size of Cluster Headache in France

13.5.2.2. Market Size of Cluster Headache by Therapies in France

13.5.3. Italy

13.5.3.1. Total Market Size of Cluster Headache in Italy

13.5.3.2. Market Size of Cluster Headache by Therapies in Italy

13.5.4. Spain

13.5.4.1. Total Market Size of Cluster Headache in Spain

13.5.4.2. Market Size of Cluster Headache by Therapies in Spain

13.5.5. United Kingdom

13.5.5.1. Total Market Size of Cluster Headache in the United Kingdom

13.5.5.2. Market Size of Cluster Headache by Therapies in the United Kingdom

13.6. Japan

13.6.1. Total Market size of Cluster Headache in Japan

13.6.2. Market Size of Cluster Headache by Therapies in Japan

14. KOL Views

15. Market Drivers

16. Market Barriers

17. SWOT Analysis

18. Unmet Needs

19. Market Access

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/